Arbitration with the University of British Columbia Arbitration With The University Of British Columbia [Member] Information related to arbitration with the University of British Columbia. Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Accretion of accumulated dividends on Preferred Shares Preferred Stock, Accretion of Redemption Discount Lease liability, non-current Operating Lease, Liability, Noncurrent Registration Statement [Axis] Registration Statement [Axis] Registration Statement Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Net loss attributable to common shareholders per share Earnings Per Share, Policy [Policy Text Block] Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Genevant Genevant Sciences Corporation [Member] Genevant Sciences Corporation [Member] Right of use asset Operating Lease, Right-of-Use Asset Investments in marketable short-term securities Debt Securities, Available-for-sale, Current Income Statement Location [Axis] Income Statement Location [Axis] Share price (in USD per share) Share Price Range [Domain] Statistical Measurement [Domain] Deficit Retained Earnings (Accumulated Deficit) Other milestone and royalty payments Other Milestone and Royalty Payments [Member] Other Milestone and Royalty Payments [Member] Litigation Case [Domain] Litigation Case [Domain] US treasury bills US Treasury Bill Securities [Member] Statement of Stockholders' Equity [Abstract] Issuance of common shares pursuant to ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Segment information Segment Reporting, Policy [Policy Text Block] Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Proceeds from Sale of Property, Plant, and Equipment Proceeds from Sale of Property, Plant, and Equipment Equity investment Equity Method Investments Revenue from Contract with Customer [Abstract] Income Statement [Abstract] Schedule of deferred collaborations and contracts revenue Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Entity Registrant Name Entity Registrant Name Other non-current assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Investment, Name [Axis] Investment, Name [Axis] Issuance of common shares pursuant to exercise of options Proceeds from Stock Options Exercised Nov 2021 Registration Stmt [Member] Nov 2021 Registration Stmt [Member] Nov 2021 Registration Stmt (Decrease)/increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Related Party Transaction [Axis] Related Party Transaction [Axis] Entity File Number Entity File Number US government money market fund US Government Money Marke tFund [Member] US Government Money Marke tFund Income Tax Expense (Benefit) Income Tax Expense (Benefit) Effective annual interest rate on royalty liability Effective Annual Interest Rate Of Royalty Liability Effective Annual Interest Rate Of Royalty Liability Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] October 2021 Prospectus Supplement October 2021 Prospectus Supplement [Member] October 2021 Prospectus Supplement Investment Type [Axis] Investment Type [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Research and development services Research And Development Services [Member] Research And Development Services [Member] Sale of Stock [Domain] Sale of Stock [Domain] Certain fair value adjustments to liability stock option awards Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Vaccitech [Abstract] Vaccitech [Member] Vaccitech Organization, Consolidation and Presentation of Financial Statements [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Method Investments and Joint Ventures [Abstract] Statement of Financial Position [Abstract] Enantigen's Selling Shareholders Enantigen's Selling Shareholders [Member] Enantigen's Selling Shareholders Anti-dilutive common shares excluded from calculation of loss per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Contingent consideration Fair value of contingent consideration Liability at beginning of the period Liability at end of the period Business Combination, Contingent Consideration, Liability, Noncurrent Cumulative Collaboration Revenue Recognized Contract with Customer, Liability, Revenue Recognized Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Research and development Research and Development Expense [Member] Product and Service [Axis] Product and Service [Axis] Sale of Stock [Axis] Sale of Stock [Axis] Preferred stated value (in USD per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Axis] Business Acquisition [Axis] Equity Component [Domain] Equity Component [Domain] Unrealized loss on available-for-sale securities Debt Securities, Available-for-sale, Unrealized Gain (Loss) Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Equity Award [Domain] Award Type [Domain] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Local Phone Number Local Phone Number Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Schedule of changes in fair value of contingent consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Assets Assets [Abstract] Related Party Transactions [Abstract] Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Non-cash interest expense Non Cash Interest Expense Related To Sale Of Future Royalties Non Cash Interest Expense Related To Sale Of Future Royalties Products and Services [Table] Products and Services [Table] One-Time Upfront Cash Payment One-Time Upfront Cash Payment [Member] One-Time Upfront Cash Payment Cash equivalents Cash Equivalents [Member] Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Investments in marketable securities, non-current Debt Securities, Available-for-sale, Noncurrent Purchase of investments Payments to Acquire Investments Gross proceeds from sale of royalty interest. before advisory fees Gross Proceeds From Royalty Interest Sold Gross Proceeds From Royalty Interest Sold Royalty Interest Sold, Annual Revenue Threshold Of Highest Tier Annual Revenue Threshold Annual Revenue Threshold Jefferies LLC Jefferies LLC [Member] Jefferies LLC Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Investments in marketable securities, current Debt Securities, Available-for-sale Disposition of investments Proceeds from Sale, Maturity and Collection of Investments Deficit Retained Earnings [Member] Short-term securities Short-term Investments [Member] Counterparty Name [Domain] Counterparty Name [Domain] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc [Member] Alnylam Pharmaceuticals, Inc Research and development accruals Accrued Research And Development Research and development accruals Other Liabilities Disclosure [Abstract] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Proceeds from Collaborators Proceeds from Collaborators Jan 2020 Prospectus Supplement Jan 2020 Prospectus Supplement [Member] Jan 2020 Prospectus Supplement Other Deferred Costs, Gross Other Deferred Costs, Gross Investments in marketable long-term securities, Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Noncurrent Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Customer [Axis] Customer [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Liability related to sale of future royalties Net liability related to sale of future royalties - beginning balance Net liability related to sale of future royalties - ending balance Liability Related To Sale Of Future Royalties, Noncurrent Liability Related To Sale Of Future Royalties, Noncurrent Options granted during period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Potential Milestone Payments Potential Milestone Payments Represents the potential milestone payments amount. Schedule of stock based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Deferred Revenue, Noncurrent Deferred Revenue, Noncurrent Title of 12(b) Security Title of 12(b) Security Issuance of common shares pursuant to the Open Market Sale agreement Proceeds from issuance of shares under the agreement Proceeds from Issuance of Common Stock Deferred license revenue Increase (Decrease) in Deferred Revenue Total assets Assets Contingencies and Commitments [Table] Contingencies and Commitments [Table] Investment, Name [Domain] Investment, Name [Domain] Number of wholly-owed subsidiaries Wholly Owned Subsidiaries Included in Financial Statements Represents the number of wholly owned subsidiaries included in the reporting of the financial statements. Plan Name [Domain] Plan Name [Domain] Basic (in USD per share) Earnings Per Share, Basic Sale Agreement [Member] Sale Agreement [Member] Sale Agreement Net loss attributable to common shares Net Income (Loss) Available to Common Stockholders, Basic Document Type Document Type Research and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Development and regulatory milestones payment per licensed compound series, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per License License Agreement, Maximum Development and Regulatory Milestone Payments Per License Royalty guarantees commitments percentage Royalty Guarantees Commitments Percentage Represents the royalty guarantees commitments percentage. Number of royalty entitlements Royalty Entitlements Royalty Entitlements Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Non-cash royalty revenue Non-Cash Royalty [Member] Non-Cash Royalty Share Purchase Agreement Share Purchase Agreement [Member] Share Purchase Agreement Premiums Earned, Net Premiums Earned, Net Non-cash royalty revenue Liability From Sale Of Future Royalties, Non Cash Royalty Income Liability From Sale Of Future Royalties, Non Cash Royalty Income Debt Securities, Noncurrent Debt Securities, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Sub-licensing revenue percentage Sub-licensing revenue Percentage Sub-licensing revenue Percentage Significant accounting policies Significant Accounting Policies [Text Block] Assembly Biosciences, Inc. Assembly Biosciences, Inc. [Member] Assembly Biosciences, Inc. Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Preferred stock dividend rate as a percent Preferred Stock, Dividend Rate, Percentage Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in USD per share) Earnings Per Share, Diluted Payroll accruals Accrued Payroll Current Accrued Payroll Current Weighted average number of common shares Weighted Average Number Of Common Shares [Abstract] Weighted average number of common shares Non-cash royalty revenue Non-cash royalty revenue Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Plan Name [Axis] Plan Name [Axis] Assets Assets, Fair Value Disclosure [Abstract] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Long-term Debt Long-term Debt Total deferred license revenue Contract with Customer, Liability Total Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Open Market Sale Agreement Open Market Sale Agreement [Member] Open Market Sale Agreement Entity Small Business Entity Small Business Related Party Transaction [Line Items] Related Party Transaction [Line Items] Items applicable to preferred shares: Preferred Stock Dividends and Other Adjustments [Abstract] Recovery of Direct Costs Recovery of Direct Costs Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] US government agency bonds US Government Agency Bonds [Member] US Government Agency Bonds [Member] Total liabilities and stockholders’ equity Liabilities and Equity Future royalty payments Royalty Payable Represents the royalty payable. Other accrued liabilities Other Accrued Liabilities, Current Costs related to collaboration Other Cost and Expense, Operating Investments, Debt and Equity Securities [Abstract] Fair value measurements Fair Value Disclosures [Text Block] Depreciation Depreciation, Depletion and Amortization Additional paid-in capital Additional Paid in Capital Arbutus Plans Arbutus Plans [Member] Arbutus Plans [Member] Assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Accounts payable and accrued liabilities Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Convertible Preferred Stock Convertible Preferred Stock [Member] Marketable Securities [Table] Marketable Securities [Table] Common shares, shares outstanding (in shares) Common Stock, Shares, Outstanding Income from services (less than) Related Party Transaction, Other Revenues from Transactions with Related Party Investments in marketable securities, non-current Long-term Investments Financial Instruments [Domain] Financial Instruments [Domain] Operating expenses Operating Expenses [Abstract] Ownership interest in equity method investment (as a percentage) Equity Method Investment, Ownership Percentage Entity Interactive Data Current Entity Interactive Data Current Investments in marketable short-term securities, Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Current Revenue Revenues [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Issuance of common shares pursuant to exercise of options Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Document Period End Date Document Period End Date Change in fair value of contingent consideration Increase (decrease) in fair value of contingent consideration Increase in fair value of liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Entity Central Index Key Entity Central Index Key Effect of foreign exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Total Financial and Nonfinancial Liabilities, Fair Value Disclosure Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Liability classified stock options Employee Stock Option, Liability Classified [Member] Employee Stock Option, Liability Classified [Member] Income Statement Location [Domain] Income Statement Location [Domain] Amortization of Other Deferred Charges Amortization of Other Deferred Charges Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Investments in marketable securities, Gross Unrealized Gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Short-term investments Investments, Fair Value Disclosure Entity Address, State or Province Entity Address, State or Province Jan 2020 Registration Stmt [Member] Jan 2020 Registration Stmt [Member] Jan 2020 Registration Stmt Loss contingency, damages sought for allegedly unpaid royalties Loss Contingency, Damages Sought, Value Property and equipment, net of accumulated depreciation of $10,475 (December 31, 2021: $9,374) Property, Plant and Equipment, Net Total operating expenses Operating Expenses Jan 2020 Oct 2020 and Nov 2021 Registration Stmts Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member] Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member] Entitlement of royalties to be received Royalty Interest Sold, Maximum Royalties For Buyer Royalty Interest Sold, Maximum Royalties For Buyer Preferred shares dividends accrued Dividends, Preferred Stock, Cash Cash Investments and Cash Current liabilities: Liabilities, Current [Abstract] Issuance of common shares pursuant to the Open Market Sale Agreement Issuance of common shares pursuant to the agreement Stock Issued During Period, Value, New Issues General and administrative General and Administrative Expense Trading Symbol Trading Symbol Acuitas Therapeutics, Inc. Acuitas Therapeutics Inc. [Member] Acuitas Therapeutics Inc. Loss per share Earnings Per Share [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Related Party Transaction [Domain] Related Party Transaction [Domain] Accounting Policies [Abstract] Revenues Revenues Issuance of common shares pursuant to the Open Market Sales Agreement (in shares) Stock Issued During Period, Shares, New Issues Professional fee accruals Accrued Professional Fees, Current Document Transition Report Document Transition Report Changes in fair value of liability option Changes In Fair Value of Liability Option [Table Text Block] Changes In Fair Value of Liability Option [Table Text Block] Foreign exchange loss Foreign Currency Transaction Gain (Loss), before Tax Issued and outstanding: 152,711,702 (December 31, 2021: 144,987,736) Common Stock, Value, Issued Dividend accretion of convertible preferred shares Preferred Stock Dividends and Other Adjustments Total other income (loss) Nonoperating Income (Expense) Fair value of liability-classified options exercised in the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value Basis of presentation Basis of Accounting, Policy [Policy Text Block] Liabilities Liabilities, Fair Value Disclosure [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Allocated share-based compensation expense Share-based Payment Arrangement, Expense Transaction costs on sale of royalties Transaction Costs Related To Sale Of Future Royalties Transaction Costs Related To Sale Of Future Royalties Aggregate sale price of common shares under agreement Common Stock, Value, Subscriptions Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Non-cash interest expense Liability From Sale Of Future Royalties, Non Cash Expense Liability From Sale Of Future Royalties, Non Cash Expense Entity Emerging Growth Company Entity Emerging Growth Company Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Entity Current Reporting Status Entity Current Reporting Status Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners ONPATTRO [Member] ONPATTRO, global net sales [Member] ONPATTRO, global net sales Number of common shares issued upon conversion of preferred shares Convertible Preferred Stock, Shares Issued upon Conversion Investments [Domain] Investments [Domain] Collaborations and licenses Collaboration And Contracts [Member] Collaboration And Contracts [Member] Net accretion and amortization of investments in marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Long-term securities Long-Term Investments [Member] Long-Term Investments Ownership [Axis] Ownership [Axis] Development and regulatory milestones payment per royalty, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per Royalty License Agreement Maximum Development And Regulatory Royalty Payment per Royalty Counterparty Name [Axis] Counterparty Name [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Payables and Accruals [Abstract] Investments in marketable securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Legal Entity [Axis] Legal Entity [Axis] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment Cover [Abstract] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Beginning balance (in shares) Ending balance (in shares) Shares, Issued Class of Stock [Axis] Class of Stock [Axis] Contingencies and Commitments [Line Items] Contingencies and Commitments [Line Items] Number of shares issued under agreement (in sales) Sale of Stock, Number of Shares Issued in Transaction Realized gains or losses Debt Securities, Realized Gain (Loss) Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Current assets: Assets, Current [Abstract] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Decrease in fair value of liability Increase (Decrease) in Fair Value of Liability Classified Options Increase (Decrease) in Fair Value of Liability Classified Options Qilu Pharmaceutical Co, LTD. [Member] Qilu Pharmaceutical Co, LTD. [Member] Qilu Pharmaceutical Co, LTD. Deferred Revenue, Current Deferred Revenue, Current Cash and cash equivalents Cash equivalents, Fair Value Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Revenue from collaborations and licenses and Deferred Revenue Revenue from Contract with Customer [Policy Text Block] Issuance of common shares pursuant to exercise of options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Financial Instrument [Axis] Financial Instrument [Axis] Entity [Domain] Entity [Domain] Unrealized gain (loss) on available-for-sale securities Other Comprehensive Income (Loss), Net of Tax Oct 2020 Registration Stmt [Member] Oct 2020 Registration Stmt [Member] Oct 2020 Registration Stmt Recurring Fair Value, Recurring [Member] US government bonds US Government Bonds [Member] US Government Bonds [Member] Shareholders’ equity Stockholders' Equity Note Disclosure [Text Block] Employee Stock Option Share-based Payment Arrangement, Option [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Document Quarterly Report Document Quarterly Report Statement of Cash Flows [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Schedule of activity related to the net liability from inception of the Agreement Liabilities Related To Sale Of Future Royalties Roll Forward [Table Text Block] Liabilities Related To Sale Of Future Royalties Roll Forward Common Shares Common Stock [Member] Interest income Investment Income, Interest Entity Address, Address Line One Entity Address, Address Line One US Corporate Bonds [Member] US Corporate Bonds [Member] US Corporate Bonds Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net change in operating items: Increase (Decrease) in Operating Capital [Abstract] Issuance of common shares pursuant to ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Accumulated depreciation of property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Loss from operations Operating Income (Loss) OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] General and administrative General and Administrative Expense [Member] Principles of consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Liability-classified options Liability at beginning of the period Liability at end of the period Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure Lease liability, current Operating Lease, Liability, Current Investments in marketable securities, Gross Unrealized Loss Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Collaborations, contracts and licensing agreements Collaborative Arrangement Disclosure [Text Block] Total current liabilities Liabilities, Current Class of Stock [Domain] Class of Stock [Domain] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash equivalents, Amortized Cost Cash and Cash Equivalents, at Carrying Value Royalty interest, % interest [Member] Royalty interest, Percent interest Royalty interest, % interest OMERS OMERS [Member] OMERS Mar 2021 Prospectus Supplement Agreement [Member] Mar 2021 Prospectus Supplement Agreement [Member] Prospectus Supplement - Open Market Sale Agreement Mar 2021 Trade accounts payable Accounts Payable, Trade, Current Ownership [Domain] Ownership [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Income Taxes Paid Income Taxes Paid Marketable securities Marketable Securities [Table Text Block] Issuance of common shares pursuant to ESPP Proceeds from Stock Plans Other liabilities Increase (Decrease) in Other Operating Liabilities Statement [Table] Statement [Table] Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Registration Statement [Domain] Registration Statement [Domain] Registration Statement [Domain] Maximum Maximum [Member] Range [Axis] Statistical Measurement [Axis] X-Chem, Inc. and Proteros [Member] X-Chem, Inc. and Proteros [Member] X-Chem, Inc. and Proteros Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Sale of future royalties Liabilities Related To Sale Of Future Royalties [Text Block] Liabilities Related To Sale Of Future Royalties Summary of collaborations Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Total liabilities Liabilities Stockholders' Equity Note [Abstract] March 2022 Prospectus Supplement [Member] March 2022 Prospectus Supplement [Member] March 2022 Prospectus Supplement Premium on closing stock price (as a percent) Premium on Closing Stock Price Premium on Closing Stock Price Award Type [Axis] Award Type [Axis] Preferred Shares Preferred Stock [Member] Weighted average exercise price (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Aug 2020 Prospectus Supplement Aug 2020 Prospectus Supplement [Member] Aug 2020 Prospectus Supplement FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Arbutus Inc. Arbutus Inc. [Member] Arbutus Inc. [Member] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Roivant Sciences Ltd Roivant Sciences Ltd [Member] Roivant Sciences Ltd [Member] Change in fair value of contingent consideration Increase (Decrease) In Fair Value Of Contingent Consideration Liability Increase (Decrease) In Fair Value Of Contingent Consideration Liability Common shares, shares issued (in shares) Common Stock, Shares, Issued Revenue from collaborations and licenses License [Member] City Area Code City Area Code Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Nature of business and future operations Nature of Operations [Text Block] Investment in Genevant Equity Method Investments and Joint Ventures Disclosure [Text Block] Entity Address, City or Town Entity Address, City or Town Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Related party transactions Related Party Transactions Disclosure [Text Block] Ownership percentage by noncontrolling owners after conversion Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Non-cash items: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Bona fide collaboration Percentage Bona fide collaboration Percentage Bona fide collaboration Percentage